Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 7, 2022; 28(45): 6314-6327
Published online Dec 7, 2022. doi: 10.3748/wjg.v28.i45.6314
Published online Dec 7, 2022. doi: 10.3748/wjg.v28.i45.6314
Liver injury induced by COVID 19 treatment – what do we know?
Lekha Saha, Soumya Vij, Kajal Rawat, Department of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India
Author contributions: All authors were equally involved in the literature search and manuscript writing and editing.
Conflict-of-interest statement: All authors report having no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Lekha Saha, MBBS, MD, MNAMS, Full Professor, Department of Pharmacology, Post Graduate Institute of Medical Education and Research, Sector 12, Chandigarh 160012, India. lekhasaha@rediffmail.com
Received: September 12, 2022
Peer-review started: September 12, 2022
First decision: September 29, 2022
Revised: October 7, 2022
Accepted: November 17, 2022
Article in press: November 17, 2022
Published online: December 7, 2022
Processing time: 80 Days and 22.7 Hours
Peer-review started: September 12, 2022
First decision: September 29, 2022
Revised: October 7, 2022
Accepted: November 17, 2022
Article in press: November 17, 2022
Published online: December 7, 2022
Processing time: 80 Days and 22.7 Hours
Core Tip
Core Tip: Liver damage is cited as the most frequent clinical extrapulmonary manifestation in a number of coronavirus disease 2019 (COVID-19) clinical trials. Herein, we summarized the available clinical data concerning liver injury during COVID-19. Transaminases and bilirubin levels were high in a significant majority of patients; however, the exact cause of liver damage is not entirely clear. A worse clinical course of COVID-19 may be associated with severe liver enzyme abnormalities. However, it is impossible to rule out a number of additional cofactors (drug-induced liver damage, an inflammatory response to an infection, hypoxic hepatitis, or underlying liver disease).